Results 11 to 20 of about 61,606 (299)
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia [PDF]
, 2017 Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown.
Hodges, James S. +8 more
core +2 more sources
Turkish Journal of Hematology, 2020 Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV). Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at ...
Yahya Büyükaşık +20 more
doaj +1 more source
MicroNIR/chemometrics assessement of occupational exposure to hydroxyurea [PDF]
, 2018 Portable Near Infrared spectroscopy (NIRs) coupled to chemometrics was investigated for the first time as a novel entirely on-site approach for occupational exposure monitoring in pharmaceutical field.
Materazzi, S., Risoluti, R.
core +2 more sources
Beliefs about hydroxyurea in youth with sickle cell disease
Hematology/Oncology and Stem Cell Therapy, 2018 Background: Hydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence,
Sherif M. Badawy +2 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Hydroxyurea has long been used for the treatment of sickle cell anemia (SCA), and its clinical effectiveness is related to the induction of fetal hemoglobin (HbF), a major modifier of SCA phenotypes.
Rahyssa Rodrigues Sales +5 more
doaj +1 more source
JMIR Research Protocols, 2020 BackgroundHydroxyurea prevents disease complications among patients with sickle cell disease (SCD). Although its efficacy has been endorsed by the National Health Lung and Blood Institute evidence-based guidelines, its adoption is low, both by patients ...
Hankins, Jane S +17 more
doaj +1 more source
Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. [PDF]
, 2016 BACKGROUND: Priapism is unwanted painful penile erection that affects about 36% of boys and men with sickle cell disease (SCD) most of whom have sickle cell anemia. Clinically, priapism could be stuttering, minor, or major.
Adeyoju +23 more
core +2 more sources
Health and Quality of Life Outcomes, 2017 Background Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients’ perceptions are poorly understood amongst ...
Sherif M. Badawy +5 more
doaj +1 more source
Haematologica, 2017 Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone or with the combination of hydroxyurea plus phlebotomies.
Alberto Alvarez-Larrán +28 more
doaj +1 more source
Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients [PDF]
, 2017 Background: Human erythropoiesis is characterized by distinct gene expression profiles at various developmental stages. Previous studies suggest that fetal-to-adult hemoglobin switch is regulated by a complex mechanism, in which many key players still ...
Ali, Bassam R. +11 more
core +5 more sources